• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by PainReform Ltd.

    8/29/24 4:00:27 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRFX alert in real time by email
    SC 13D/A 1 ea0212819-13da1liapure_pain.htm AMENDMENT NO. 1 TO SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    (Amendment No. 1)

     

    PainReform Ltd.

    (Name of Issuer)

     

    Ordinary shares, no par value

    (Title of Class of Securities)

     

    M77798128

    (CUSIP Number)

     

    August 28, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), (f) or (g), check the following box: ☐

     

    Note: Schedules filed in paper format should include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

     

     

     

     

     

    CUSIP No. M77798128

     

    1

    NAME OR REPORTING PERSON

     

    L.I.A. Pure Capital Ltd. (1)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☒

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS

     

    WC

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ☐

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    Israel

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7

    SOLE VOTING POWER

     
    250,000

    8

    SHARED VOTING POWER

     
    0

    9

    SOLE DISPOSITIVE POWER

     
    250,000

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    250,000

    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES

     

    ☐

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    3.55% (2)

    14

    TYPE OF REPORTING PERSON

     

    CO

     

    (1) Kfir Silberman is the officer, sole director, chairman of the board of directors and control shareholder of L.I.A. Pure Capital Ltd. (“Pure Capital”).

     

    (2) Based on a total of 7,026,243 ordinary shares, no par value, of PainReform Ltd. (the “Issuer” and the “Ordinary Shares”, respectively) outstanding as of August 26, 2024 (based on the Issuer’s amended proxy statement filed under its Amendment No. 1 to the Report of Foreign Private Issuer on Form 6-K on August 28, 2024).

     

    -2-

     

     

    CUSIP No. M77798128

     

    1

    NAME OR REPORTING PERSON

     

    Kfir Silberman (1)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☒

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS

     

    AF

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ☐

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    Israel

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7

    SOLE VOTING POWER

     

    250,000

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    250,000

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    250,000

    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES

     

    ☐

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    3.55% (2)

    14

    TYPE OF REPORTING PERSON

     

    IN

     

    (1) Kfir Silberman is the officer, sole director, chairman of the board of directors and control shareholder of Pure Capital.

     

    (2) Based on a total of 7,026,243 Ordinary Shares of the Issuer outstanding as of August 26, 2024 (based on the Issuer’s amended proxy statement filed under its Amendment No. 1 to the Report of Foreign Private Issuer on Form 6-K on August 28, 2024).

     

    -3-

     

     

    EXPLANATORY NOTE

     

    This Amendment No. 1 to the Schedule 13D (this “Amendment No. 1”) relates to the ordinary shares, no par value, of PainReform Ltd., a company organized under the laws of the State of Israel (the “Issuer”), and amends the Schedule 13D filed on August 26, 2024 (the “Original Schedule 13D”, and together with the Amendment No. 1, the “Schedule 13D”). Capitalized terms used and not defined in this Amendment No. 1 have the meanings set forth in the Original Schedule 13D.

     

    This Amendment No. 1 amends Item 5 and Item 7 as set forth below. As a result of certain transactions in the Ordinary Shares, and based on the information provided by the Company in the Issuer’s amended proxy statement filed under its Amendment No. 1 to the Report of Foreign Private Issuer on Form 6-K on August 28, 2024, as of August 29, 2024, the Reporting Persons ceased to be the beneficial owner of more than five percent of the Ordinary Shares. The filing of this Amendment No. 1 represents the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons.

     

    Item 5. Interests in Securities of the Issuer.
       
      (a)-(b) The information included herein is based on a total of 7,026,243 Ordinary Shares of the Issuer outstanding as of August 26, 2024 (based on the Issuer’s amended proxy statement filed under its Amendment No. 1 to the Report of Foreign Private Issuer on Form 6-K on August 28, 2024).
       
      Pure Capital has the sole dispositive and voting power over 250,000 Ordinary Shares, representing approximately 3.55% of the outstanding share capital of the Issuer.
       
      Kfir Silberman does not directly own any Ordinary Shares. Mr. Silberman, as the owner and controlling shareholder of Pure Capital, may be deemed a beneficial owner of any Ordinary Shares beneficially owned by Pure Capital.
       
      (c)-(d) Except as set forth on Schedule A of the Original Schedule 13D, there have been no transactions with respect to the Ordinary Shares during the sixty days prior to the date hereof by the Reporting Persons.
       
      (e) As a result of certain transactions in the Ordinary Shares, and based on the information provided by the Company in the Issuer’s amended proxy statement filed under its Amendment No. 1 to the Report of Foreign Private Issuer on Form 6-K on August 28, 2024, as of August 29, 2024, the Reporting Persons ceased to be the beneficial owner of more than five percent of the Ordinary Shares. The filing of this Amendment No. 1 represents the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons.

     

    Item 7. Material to be Filed as Exhibits

     

    Exhibit 1   Joint Filing Agreement by and among L.I.A. Pure Capital Ltd. and Kfir Silberman, dated August 26, 2024 (incorporated by reference to Exhibit 1 to the Schedule 13D filed by the Reporting Persons with the SEC on August 26, 2024).

     

    -4-

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      KFIR SILBERMAN
       
      /s/ Kfir Silberman
      Kfir Silberman
       
      L.I.A. PURE CAPITAL LTD.
       
      /s/ Kfir Silberman
      Kfir Silberman
       
    Dated: August 29, 2024  

     

    -5-

    Get the next $PRFX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRFX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRFX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PainReform Provides Business Update for the Six Months Ended June 30, 2025

    TEL AVIV, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of AI-driven solar analytics technologies, today provided a business update for the six months ended June 30, 2025. Key Highlights: Completed majority investment in LayerBio, adding OcuRing™-K, a breakthrough dropless cataract therapy targeting a ~$9B global marketAdvanced PRF-110 with ongoing R&D following partially positive efficacy signals in postoperative painExpanded DeepSolar with completion of Smart Energy Management app, acceptance into NVIDIA Connect Program, and successful completion

    10/1/25 9:27:49 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform/DeepSolar Accepted into NVIDIA Connect Program

    TEL AVIV, Israel, Aug. 19, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), today announced that DeepSolar, PainReform's solar energy business unit developing next-generation AI-driven solar analytics, has been accepted into the prestigious NVIDIA Connect Program. This program is NVIDIA's premier development track for independent software vendors building transformative AI-based solutions across sectors. Participation in the program provides DeepSolar with access to NVIDIA's industry-leading AI frameworks, development tools, and engineering support. This future collaboration will support efforts to advance DeepSolar Predict, the company's breakthrough solar forecasting solution

    8/19/25 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System

    TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), today announced, through its pharmaceutical division, the closing of its previously announced investment in LayerBio, Inc., a privately held Boston-based biotechnology company advancing sustained-release drug delivery technologies in ophthalmology. With this transaction, PainReform has acquired a majority equity interest in LayerBio and plans to initiate the next clinical trial of OcuRing™-K, LayerBio's lead investigational product for pain and inflammation control following cataract surgery. This transaction positions PainReform to potentially address a large and growing clinical need in the global catarac

    8/13/25 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    SEC Filings

    View All

    SEC Form 6-K filed by PainReform Ltd.

    6-K - PAINREFORM LTD. (0001801834) (Filer)

    10/1/25 9:29:56 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PainReform Ltd.

    6-K - PAINREFORM LTD. (0001801834) (Filer)

    8/19/25 8:45:37 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PainReform Ltd.

    6-K - PAINREFORM LTD. (0001801834) (Filer)

    8/13/25 4:16:22 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

    SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

    11/14/24 4:25:42 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

    SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

    11/13/24 11:18:32 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by PainReform Ltd.

    SC 13D/A - PAINREFORM LTD. (0001801834) (Subject)

    8/29/24 4:00:27 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Leadership Updates

    Live Leadership Updates

    View All

    PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief

    HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update.  Significant events and achievements during the fourth quarter 2020 and subsequent period: Preparation for the first Phase 3 clinical trial, for patients undergoing bunionectomy surgery, is expected to begin by mid-2021Announced the engagement of Lotus Clinical Research as the Company’s clinical research organization to conduct the Phase 3 clinical trials under the leadership of Dr. Neil SinglaAnnounced the appointment of Ri

    3/18/21 9:15:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations

    HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations. Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been responsible for drug development from early phase trials through NDA filings, including managing all chemistry, manufacturing and control (CMC) activities supporting product development, clinical supplies, scale-up, regulatory submissions and commercial manufacturing

    1/6/21 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care